Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

Status

Terminated

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00417833

Enrollment

Unknown

Registered

2007-01-04

Start date

2005-12-31

Completion date

2006-07-31

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choroidal Neovascularization, Diabetic Proliferative Retinopathy, Vascular Vein Oclussion

Brief summary

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG). Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.

Interventions

DRUGIntravitreal Bevacizumab

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization * Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment * Completely studies

Exclusion criteria

Complications * Tractional Detachment * Endophthalmitis

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026